When you use our sites, PAREXEL will assign cookie files (“Cookies”) to you, which are a small amount of information we send to your web browser. Cookies enable the computers operating our websites to differentiate between visitors and to track the patterns of activities engaged in by different visitors. By clicking the Continue Browsing button or continuing to use this site, you agree to accept the PAREXEL Privacy Policy and all Cookies deployed on this site. You may choose to continue browsing with cookies, or leave the site.

PAREXEL's Jeffery Fairbairn Discusses Key Issues at DIA 2014

One of the key issues that's being discussed at DIA this year is how sponsors can lower the overall costs of drug development and how CROs can help them do that.
There are two ways that PAREXEL can really help to address this client need. The first is through our Partnership Value Model, which is a data driven tool that really helps clients think through the different levers that they can pull in order to lower the overall cost of drug development. The second is Study Optimization Services where we engage early with clients to help them write more efficient, more cost effective protocols.
Through these offerings, we are providing some of the answers to sponsors on how they can lower the cost of drug development. We're not leaving this to sponsors to find themselves. This simplifies their journey.

Previous Video

PAREXEL Strategic Partnerships: Streamlining the Journey from Molecule to Market

This short video demonstrates how a Strategic Partnership with PAREXEL uses intelligent planning, streamlin...

Next Video

PAREXEL's Alberto Grignolo, PhD, Comments on Key Trends at DIA 2014

The major topics discussed at DIA today, at this particular annual meeting, I have found to be rather patie...